66 phd-rehabilitation-engineering-computer-science Postdoctoral research jobs at Yale University
Sort by
Refine Your Search
-
(SUDs), psychiatric conditions, and other behavioral and lifestyle characteristics that impact human health using large datasets and biobanks including the Million Veteran Program (MVP), the SUD working
-
at national/international conferences Access to a broad network of collaborators at Yale and beyond Qualifications We welcome applicants with backgrounds in either experimental biology, computational biology
-
projects, we have access to large datasets including the Million Veteran Program and the Psychiatric Genomics Consortium. The ideal candidate should hold an MD or PhD, and have a strong background in human
-
projects, there are ample opportunities to tailor the needs of the lab to the skillset and interests of the individual. Candidates with MD, PhD, or MD/PhD degrees and experience in a variety of molecular
-
year at Yale in dual affiliation with the Yale Child Study Center and the Yale Center for Brain and Mind Health (CBMH). Originally rooted in clinical psychological science, the Cha Lab strives to embody
-
engineering is considered a plus. The lab has routine access to Krios and FIB-milling instruments. 2) Genome editing: Projects involve developing novel genome editing tools and optimizing in vivo delivery
-
for hearing loss in mouse models. Experiences on molecular & cellular biology, biochemistry, or AD research are preferred. Preferred qualifications also include but not limit mobility and ability to work
-
. This position offers an excellent opportunity to contribute to clinical diagnostics and translational research in the field of andrology. Qualifications: PhD in Andrology, Reproductive Biology, Molecular Biology
-
biochemistry, molecular biology, (genetics, or bacteriology) * have first-author publication(s) in peer-reviewed journals * be highly self-motivated. Ideal candidates will want to: * conduct original
-
methods for measuring genome-wide methylation signatures in blood to identify early-stage cancers or early recurrences after therapy. In addition, this platform technology is generating rich whole